Mind Medicine (MNMD) announced its Q4 financials and indicated it is making strides in developing innovative treatments for brain health ...

Johnson & Johnson JNJ decided to discontinue the Phase 3 VENTURA development program, which is evaluating aticaprant as an ...

J&J said it plans to “explore future development opportunities for aticaprant in other areas of high unmet need”. A statement ...

Among 347,468 individuals who had lived with persistent pain for over 3 months, clinical symptoms of depression and anxiety ...

NIH technology transfer offices have been barred from filing new patent applications and restricted from licensing existing ...

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...

Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion ...

Menopause can worsen symptoms of bipolar disorder. In rare cases, it may trigger bipolar disorder. Menopause is a factor when ...

Johnson & Johnson (JNJ) stock in focus as company halts Phase 3 depression therapy trials for aticaprant over efficacy ...

Johnson & Johnson has added to the opioid kappa blues. Months after Neumora reported a phase 3 flop, J&J has stopped ...

A new review has found evidence that music-based therapy may benefit people living with dementia, particularly by improving ...

Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...